APA (7th ed.) Citation

AC, G., SE, K., T, L., J, D., R, N., Y, A., . . . SM, T. (2026). SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2026.06.012

Chicago Style (17th ed.) Citation

AC, Garrido-Castro, et al. "SACI-IO HR+: A Randomized Phase II Trial of Sacituzumab Govitecan with or Without Pembrolizumab in Patients with Metastatic Hormone Receptor-positive/HER2-negative Breast Cancer." Annals of Oncology : Official Journal of the European Society for Medical Oncology 2026. https://doi.org/10.1016/j.annonc.2026.06.012.

MLA (9th ed.) Citation

AC, Garrido-Castro, et al. "SACI-IO HR+: A Randomized Phase II Trial of Sacituzumab Govitecan with or Without Pembrolizumab in Patients with Metastatic Hormone Receptor-positive/HER2-negative Breast Cancer." Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2026, https://doi.org/10.1016/j.annonc.2026.06.012.